Enhancement of coagulation caused by transfusion of artificial plasma-replacement solutions


Cite item

Full Text

Abstract

Aim. To investigate hemostasis disorders caused by massive blood transfusions of artificial plasma replacing solutions (PRS).
Material and methods. Two groups of patients were examined: 7 healthy volunteers without blood loss (group 1) and 11 healthy donors of bone marrow with intraoperative blood loss 1-2 l (group 2). Five patients of group 1 received transfusion of 12 ml/kg hydroxyethyl starch (HES) 130/0.4, two patients of group 1 received transfusion of modified gelatine solution (gelofusin). All of them received infusions (1-1.5 l) of crystalloid PRS (1-2 l) and infusion of one of colloid PRS (6-HES, 5 - gelofusin). Estimated hemodilution in group 1 was 1.17 ± 0.01 times, in group 2 it varied from 1.3 to 2.7 times (mean 1.78 ± 0.4 times). Hemostasis was studied by clot growth rate (for groups 1 and 2), endogenic thrombin potential and parameters of thromboelastography (for group 2) in plasm samples obtained before, 2.24 and 48 hours after infusion of colloid PRS.
Results. For both groups spatial clot growth rate 2 hours after hemodilution was high. Then it fell and reached baseline level 48 hours after PRS infusion. Endogenic thrombin potential and thromboelastography data (for group 2) changed by the same pattern. A hypercoagulation effect of gelofusin on parameters of thromboelastography and clot growth rate was higher than of HES 130/04.
Conclusion. Moderate hemodilution with PRS in vivo causes hypercoagulation which persisted longer than volemic effect of PRS.

References

  1. Воробьев А. И., Городецкий В. М., Шулутко Е. М., Васильев С. А. Патогенез синдрома острой массивной кровопотери. В кн.: Острая массивная кровопотеря. М.: ГЭОТАР-МЕД; 2001. 22-35.
  2. Janvrin S. B., Davies G., Greenhalgh R. M. Postoperative deep vein thrombosis caused by intravenous fluids during surgery. Br. J. Surg. 1980; 67(10): 690-693.
  3. Tuman K. J., Spiess B. D., McCarthy R. J., Ivankovich A. D. Effects of progressive blood loss on coagulation as measured by thrombelastography. Anesth. Analg. 1987; 66(9): 856-863.
  4. Ng K. F. J., Lam C. C. K., Chan L. C. In vivo effect of haemodilution with saline on coagulation: a randomized controlled trial. Br. J. Anaesth. 2002; 88(4): 475-480.
  5. Ruttmann T. G., James M. F. M., Aronson I. In vivo investigation into the effects of haemodilution with hydroxyethyl starch (200/0.5) and normal saline on coagulation. Br. J. Anaesth. 1998; 80(5): 612-616.
  6. Holte K., Kristensen B. B., Valentiner L. et al. Liberal versus restrictive fluid management in knee arthroplasty: a randomized, double-blind study. Anesth. Analg. 2007; 105(2): 465-474.
  7. Ciavarella D., Reed R. B., Baron L. et al. Clotting factor levels and the risk of diffuse microvascular bleeding in the massively transfused patient. Br. J. Haematol. 1987; 67(3): 365-368.
  8. Jesty J. The kinetics of inhibition of thrombin by antithrombin in the presence of components of the hemostatic system. Blood 1985; 66(5): 1189-1195.
  9. Jesty J. The kinetics of inhibition of a-thrombin in human plasma. J. Biol. Chem. 1986; 261(22): 10313-10318.
  10. Ruttmann T. G., James M. F. M., Lombard E .H. Haemodilution-induced enhancement of coagulation is attenuated in vitro by restoring antithrombin III to pre-dilution concentrations. Anaesth. Intensive Care 2001; 29(5): 489-493.
  11. Cинауридзе Е. И., Горбатенко А. С., Ажигирова М. А. и др. Раствор для коррекции первичных нарушений гемостаза плазмозамещающими растворами нового состава. Пат. РФ № 2300385, от 27 декабря 2005 г. (заявка № 2005140841/15; класс А61К 35/14, А61К 31/718 и А61Р 7/00).
  12. Синауридзе Е. И., Горбатенко А. С., Грибкова И. В. и др. Гиперкоагуляция, вызываемая разбавлением плазмы искусственными плазмозамещающими растворами. Технологии живых систем 2008; 5(1): 3-14.
  13. Hemker H. C., Giesen P. L., Ramjee M. et al. The thrombogram: monitoring thrombin generation in platelet-rich plasma. Thromb. Haemost. 2000; 83(4): 589-591.
  14. Hemker H. C., Giesen P., AlDieri R. et al. The calibrated automated thrombogram (CAT): a universal routine test for hyper- and hypocoagulability. Pathophysiol. Haemost. Thromb. 2002; 32(5-6): 249-253.
  15. Синауридзе Е. И., Шулутко Е. М., Щербакова О. В. и др. Методы анализа состояния гемостаза при введении пациентам препарата рекомбинантного фактора VIIа "НовоСэвен". Новое в трансфузиол. 2006; 42: 17-34.
  16. Ovanesov M. V., Krasotkina J. V., Ul'yanova L. I. et al. Hemophilia A and B are associated with abnormal spatial dynamics of clot growth. Biochim. Biophys. Acta 2002; 1572(1): 45-57.
  17. Ovanesov M. V., Lopatina E. G., Saenko E. L. et al. Effect of factor VIII on tissue factor-initiated spatial clot growth. Thromb. Haemost. 2003; 89(2): 235-242.
  18. Hartert H., Schaeder J. A. The physical and biological constants of thrombelastography. Biorrheology 1962; 1(1): 31-39.
  19. Carr M. E. Jr., Martin E. J., Kuhn J. G. et al. Monitoring of hemostatic status in four patients being treated with recombinant factor Vila. Clin. Lab. 2004; 50(9-10): 529-538.
  20. Kawabata S., Miura T., Morita T. et al. Highly sensitive peptide-4-methylcoumaryl-7-amide substrates for blood-clotting proteases and trypsin. Eur. J. Biochem. 1988; 172(1): 17-25.
  21. Mortelmans Y. J., Vermaut G., Verbruggen A. M. et al. Effects of 6% hydroxy ethyl starch and 3% modified fluid gelatin on intravascular volume and coagulation during intraoperative hemodilution. Anesth. Analg. 1995; 81(6): 1235-1242.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2009 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies